Clinical Trials
13
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:11
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (84.6%)Not Applicable
1 (7.7%)Phase 2
1 (7.7%)A Study of LM-350 in Subjects With Advanced Solid Tumours
Not Applicable
Not yet recruiting
- Conditions
- Malignant Tumors
- Interventions
- Drug: LM-350 for injection
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 55
- Registration Number
- NCT07112222
- Locations
- 🇦🇺
Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 84
- Registration Number
- NCT06873854
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 87
- Registration Number
- NCT06868199
- Locations
- 🇦🇺
Cancer Care Wollongong, Wollongong, New South Wales, Australia
🇦🇺Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Toripalimab/Tirelizumab
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 320
- Registration Number
- NCT06682780
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of LM-299 in Subjects Advanced Malignant Tumors
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 108
- Registration Number
- NCT06650566
- Locations
- 🇦🇺
One Clinical Research, Perth, West Australia, Australia
🇨🇳the first affiliated hospital of Xinxiang medical University, Xinxiang, Henan, China
🇨🇳Liaocheng people's hospital, Liaocheng, Shandong, China
- Prev
- 1
- 2
- 3
- Next
News
No news found